Deerfield Plunks Down $100 Million to Support R&D Alliance With Harvard Unive...

医疗投资公司 Deerfield 投入1亿美元,与哈佛大学组建研发联盟

2019-03-15 18:40:00 BioSpace

本文共1103个字,阅读需3分钟

标签: 医药/器械 医药 创新药
Healthcare investment firm Deerfield Management forged a research and development agreement with Harvard University to speed the development and translation of biomedical and life-science innovations into transformative treatments for patients. Deerfield provided $100 million in initial funding for the endeavor to support the alliance between the university and a newly-formed company, Lab1636. The partnership will be helmed by Harvard’s Office of Technology Development. In the announcement, Deerfield said the alliance is expected to catalyze the development of novel therapeutics and rapidly drive innovations toward clinical validation. Lab1636, which is wholly-owned by Deerfield, will support Harvard R&D projects throughout various stages of drug discovery and development, for example enabling studies to explicate the biology of disease, validate therapeutic targets, or achieve a proof-of-concept necessary for filing an Investigational New Drug (IND) application. Harvard’s R&D projects to be funded by Lab1636 will be selected by a joint advisory committee. The projects will be initiated by principal investigators from various labs across the university. The projects will generally focus on the development of novel therapeutics, ideally advancing many to a stage that would enable the filing of an IND application and, if successful, the commencement of clinical trials in patients, Deerfield said. In its announcement, Deerfield pointed out that many commercially promising innovations tend to outgrow the capabilities at the university. Those research projects require greater resources or a more focused development than the university setting can provide. In addition to funding research on campus, Lab1636 may facilitate licenses to outside companies and is equipped to provide substantial support to the launch and growth of new startups dedicated to developing Harvard technologies, Deerfield said. James E. Flynn, managing partner of Deerfield, said Harvard makes the ideal partner for this alliance. Flynn noted that the venerable academic institution has “outstanding science, breadth of technologies, and mix of esteemed junior and senior faculty constitute a fertile environment for the continuous generation of novel insights.” Those factors, as well as the university’s track record in advancing potential therapeutics makes it the perfect partner, Flynn said in a brief statement. “The sheer scope of this collaboration with Deerfield may prove transformative for Harvard research,” Vivian Berlin, managing director of strategic partnerships in OTD said. “This alliance has immense potential to bridge the development gap, ensure continuity of resources, and complement our other major translational programs, such as the Blavatnik Biomedical Accelerator.” Isaac T. Kohlberg, chief technology development officer at Harvard, said the alliance between the school and Deerfield will enhance opportunities for Harvard’s life-changing innovations to reach patients in need. “Success in a research alliance requires a partner with a long vision and operational and development expertise, as well as the financial resources, and we’re delighted to launch this initiative with Deerfield,” Kohlberg said. “We hope that our R&D alliance with Deerfield will further sustain and speed the commercialization of innovations from across the university toward societal impact.”
医疗投资公司 Deere Management 与哈佛大学( Harvard University )签订了一项研发协议,以加快生物医学和生命科学创新向患者转型治疗的发展和转化。 迪尔菲尔德为支持大学和新成立的 Lab1636公司之间的联盟提供了1亿美元的初始资金。这一合作将由哈佛技术发展办公室( Office of Technology Development )负责。在声明中,迪尔菲尔德说,该联盟预计将促进新疗法的发展,并迅速推动创新的临床验证。由 Deere 全资拥有的 Lab1636将在药物发现和开发的各个阶段支持哈佛的研发项目,例如使研究能够阐明疾病的生物学特性,验证治疗目标,或实现提交调查新药( IND )申请所必需的概念证明。 哈佛大学将由 Lab1636资助的研发项目将由一个联合咨询委员会选定。这些项目将由来自大学不同实验室的主要调查人员发起。迪尔菲尔德说,这些项目将主要集中在新型疗法的开发上,理想的做法是将许多治疗方案推进到能够提交 IND 申请的阶段,如果成功的话,将在患者中开始临床试验。 在声明中,迪尔菲尔德指出,许多具有商业前景的创新往往超过了大学的能力。这些研究项目需要比大学提供的更多的资源或更集中的发展。除了为校园研究提供资金外, Lab1636还可以为外部公司提供许可证,并为致力于开发哈佛技术的新初创企业的启动和发展提供大量支持。 John E.Flynn ,迪尔菲尔德的管理合伙人,说哈佛是这个联盟的理想伙伴。弗林指出,这所备受尊崇的学术机构“拥有卓越的科学、广泛的技术,以及受人尊敬的初级和高级教师,构成了持续不断产生新见解的肥沃环境。”弗林在一份简短声明中表示,这些因素,以及该校在推进潜在疗法方面的良好记录,使其成为完美的合作伙伴。 OTD 战略伙伴关系董事总经理维维维安•柏林( Vivian Berlin )表示:“与迪尔菲尔德的合作范围之广,可能证明对哈佛的研究具有变革性。”“这个联盟有巨大潜力弥合发展差距,确保资源的连续性,并补充我们的其他主要翻译项目,如 Blavatnik 生物医学加速器。” 哈佛大学( Harvard )首席技术开发官艾萨克· T ·科尔伯格( Isaac T . Kohlberg )表示,哈佛与迪尔菲尔德的联盟将为哈佛改变生活的创新提供更多机会,帮助有需要的患者。 Kohlberg 说:“研究联盟的成功需要合作伙伴具备长远的愿景、运营和发展专业知识以及财政资源,我们很高兴与 Deere 合作推出这一举措。”“我们希望,我们与 Deere 的研发联盟将进一步支持和加快创新从整个大学走向社会影响的商业化进程。”